KLF2/4 antibody (AA 415-513)

Catalog No. ABIN737121

Product Details anti-KLF2/4 Antibody

Target: KLF2/4 (Kruppel-Like Factor 2/4 (KLF2/4))

Binding Specificity: AA 415-513

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This KLF2/4 antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), ELISA

Specificity: This antibody may crossreact with KLF2 due to high sequence similarity.

Cross-Reactivity: Human, Mouse, Rat

Predicted Reactivity: Cow,Sheep,Pig,Horse,Chicken,Guinea Pig

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human KLF4

Isotype: IgG

Application Details

Application Notes: WB 1:300-5000
ELISA 1:500-1000
FCM 1:20-100
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Expiry Date: 12 months

References for anti-KLF2/4 antibody (ABIN737121)

Verma, Lovren, Pan, Yanagawa, Deb, Karkhanis, Quan, Teoh, Feder-Elituv, Moussa, Souza, Fremes: "Pedicled no-touch saphenous vein graft harvest limits vascular smooth muscle cell activation: the PATENT saphenous vein graft study." in: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, Vol. 45, Issue 4, pp. 717-25, (2014) (PubMed).

El-Sayed, Zhang, Zhang, Liu, Abbott, Zhang, Li: "Pluripotent state induction in mouse embryonic fibroblast using mRNAs of reprogramming factors." in: International journal of molecular sciences, Vol. 15, Issue 12, pp. 21840-64, (2014) (PubMed).

Lovren, Pan, Quan, Singh, Shukla, Gupta, Steer, Ingram, Gupta, Al-Omran, Teoh, Marsden, Verma: "MicroRNA-145 targeted therapy reduces atherosclerosis." in: Circulation, Vol. 126, Issue 11 Suppl 1, pp. S81-90, (2012) (PubMed).

Target Details for KLF2/4

Target: KLF2/4 (Kruppel-Like Factor 2/4 (KLF2/4))

Abstract: KLF2/4 Products

Background:

Synonyms: EZF, GKLF, Krueppel-like factor 4, Epithelial zinc finger protein EZF, Gut-enriched krueppel-like factor, KLF4

Background: Transcription factor, can act both as activator and as repressor. Binds the 5'-CACCC-3' core sequence. Binds to the promoter region of its own gene and can activate its own transcription. Regulates the expression of key transcription factors during embryonic development. Plays an important role in maintaining embryonic stem cells, and in preventing their differentiation. Required for establishing the barrier function of the skin and for postnatal maturation and maintenance of the ocular surface. Involved in the differentiation of epithelial cells and may also function in skeletal and kidney development. Contributes to the down-regulation of p53/TP53 transcription.

Gene ID: 9314

UniProt: O43474